title: Pilot proof of concept clinical trials of Stochastic Targeted (STAR) glycemic control.
abstract: BACKGROUND
  Tight glycemic control (TGC) has shown benefits but has been difficult to achieve consistently. STAR (Stochastic TARgeted) is a flexible, model-based TGC approach directly accounting for intra- and inter- patient variability with a stochastically derived maximum 5% risk of blood glucose (BG) < 4.0 mmol/L. This research assesses the safety, efficacy, and clinical burden of a STAR TGC controller modulating both insulin and nutrition inputs in pilot trials.
  
  
  METHODS
  Seven patients covering 660 hours. Insulin and nutrition interventions are given 1-3 hourly as chosen by the nurse to allow them to manage workload. Interventions are calculated by using clinically validated computer models of human metabolism and its variability in critical illness to maximize the overlap of the model-predicted (5-95th percentile) range of BG outcomes with the 4.0-6.5 mmol/L band while ensuring a maximum 5% risk of BG < 4.0 mmol/L. Carbohydrate intake (all sources) was selected to maximize intake up to 100% of SCCM/ACCP goal (25 kg/kcal/h). Maximum insulin doses and dose changes were limited for safety. Measurements were made with glucometers. Results are compared to those for the SPRINT study, which reduced mortality 25-40% for length of stay ≥3 days. Written informed consent was obtained for all patients, and approval was granted by the NZ Upper South A Regional Ethics Committee.
  
  
  RESULTS
  A total of 402 measurements were taken over 660 hours (~14/day), because nurses showed a preference for 2-hourly measurements. Median [interquartile range, (IQR)] cohort BG was 5.9 mmol/L [5.2-6.8]. Overall, 63.2%, 75.9%, and 89.8% of measurements were in the 4.0-6.5, 4.0-7.0, and 4.0-8.0 mmol/L bands. There were no hypoglycemic events (BG < 2.2 mmol/L), and the minimum BG was 3.5 mmol/L with 4.5% < 4.4 mmol/L. Per patient, the median [IQR] hours of TGC was 92 h [29-113] using 53 [19-62] measurements (median, ~13/day). Median [IQR] results: BG, 5.9 mmol/L [5.8-6.3]; carbohydrate nutrition, 6.8 g/h [5.5-8.7] (~70% goal feed median); insulin, 2.5 U/h [0.1-5.1]. All patients achieved BG < 6.1 mmol/L. These results match or exceed SPRINT and clinical workload is reduced more than 20%.
  
  
  CONCLUSIONS
  STAR TGC modulating insulin and nutrition inputs provided very tight control with minimal variability by managing intra- and inter- patient variability. Performance and safety exceed that of SPRINT, which reduced mortality and cost in the Christchurch ICU. The use of glucometers did not appear to impact the quality of TGC. Finally, clinical workload was self-managed and reduced 20% compared with SPRINT.
authors.affiliation: Department of Mechanical Engineering, Centre for Bio-Engineering, University of Canterbury, Christchurch, New Zealand. geoff.chase@canterbury.ac.nz.
authors.forename: Alicia
authors.initials: A
authors.lastname: Evans
authors.forename: Geoffrey M
authors.initials: GM
authors.lastname: Shaw
authors.forename: Aaron
authors.initials: A
authors.lastname: Le Compte
authors.forename: Chia-Siong
authors.initials: CS
authors.lastname: Tan
authors.forename: Logan
authors.initials: L
authors.lastname: Ward
authors.forename: James
authors.initials: J
authors.lastname: Steel
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Pretty
authors.forename: Leesa
authors.initials: L
authors.lastname: Pfeifer
authors.forename: Sophie
authors.initials: S
authors.lastname: Penning
authors.forename: Fatanah
authors.initials: F
authors.lastname: Suhaimi
authors.forename: Matthew
authors.initials: M
authors.lastname: Signal
authors.forename: Thomas
authors.initials: T
authors.lastname: Desaive
authors.forename: J Geoffrey
authors.initials: JG
authors.lastname: Chase